Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 333 clinical trials
Metformin and Prevention of Cardiovascular Events in Patients With Acute Myocardial Infarction and Prediabetes (MIMET) (MIMET)

with newly detected prediabetes (identified by oral glucose tolerance test, HbA1c or fasting glucose levels).

metformin
hemoglobin a1c
plasma glucose
fasting
diabetes
  • 0 views
  • 23 Mar, 2022
  • 1 location
iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)

treatment. Health measurement/Observation: change in HbA1c as the primary endpoint. Intervention name: iGlarLixi and IDegAsp Participant sex: male and female

metformin
hemoglobin a1c
type 2 diabetes mellitus
body mass index
alpha-glucosidase inhibitor
  • 0 views
  • 15 Jul, 2022
  • 20 locations
iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)

treatment. Health measurement/Observation: change in HbA1c as the primary endpoint. Intervention name: iGlarLixi and IDegAsp Participant sex: male and female

metformin
hemoglobin a1c
type 2 diabetes mellitus
body mass index
alpha-glucosidase inhibitor
  • 0 views
  • 20 Jul, 2022
  • 19 locations
Zinc Chromium Vitamin C and Copper Combination Supplement for Prediabetes Progression

(HbA1c). However, the eficacy of a combined zinc, chromium, vitamin C, and copper (ZCC) in decreasing blood glucose in prediabetic people has never been performed. The primary objective of this

glucose tolerance test
hemoglobin a1c
insulin
plasma glucose
oral glucose tolerance test
  • 0 views
  • 31 Aug, 2021
  • 1 location
Effectiveness of a Multimodal Intervention on Function in Older Frail People With Diabetes in Latinamerican (DIABFRAIL)

): learning phases in clinical trial site for 3-4 first week (coincident with the educational program sessions) and the rest at home. Adaptation of targets of HbA1c and blood pressure (BP). UCG Usual

  • 0 views
  • 30 Apr, 2022
  • 1 location
Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke

within 3 months, diabetes mellitus with Hba1C > 7%, taking metformin currently or previously, and estimated glomerular filtration rate ≥ 45 mL/min/1.73 m2. Eligible patients who sign the informed

metformin
ischemic stroke
hemoglobin a1c
pioglitazone
diabetes
  • 0 views
  • 24 Mar, 2022
  • 1 location
Clinic to Community Navigation to Improve Diabetes Outcomes (CCN)

., Goal: Our goal focuses on reducing HbA1c, BMI, blood pressure, lipids, and waist circumference and improving T2DM self-management and clinic attendance. Leveraging local assets, including faith

hemoglobin a1c
diabetes mellitus
hypoglycemia
type 2 diabetes mellitus
glycosylated hemoglobin
  • 190 views
  • 04 Mar, 2022
  • 1 location
Impact of Donor Diabetes on DMEK Success and Endothelial Cell Loss (DEKS)

This double-masked multi-center trial will evaluate the association of diabetes in the cornea donor with transplant success and loss of endothelial cells one year following Descemet membrane endothelial keratoplasty (DMEK). Study eyes will be assigned to receive either a cornea from a donor without diabetes or a cornea from a …

  • 0 views
  • 26 Mar, 2022
  • 2 locations
EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Participants With HR+, HER2-, Advanced Breast Cancer With a PIK3CA Mutation Following Progression on/After Endocrine-based Therapy (EPIK-B4)

This is a Phase II, multicenter, randomized, open-label, active-controlled trial designed to assess the safety and efficacy of the combination of dapagliflozin plus metformin extended release (XR) compared with metformin XR during treatment with alpelisib plus fulvestrant in participants with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation following …

HER2
estrogen
fulvestrant
mammogram
PIK3CA
  • 1 views
  • 22 Sep, 2022
  • 22 locations
Investigational Study of Delayed Release Metformin (DREAM-T2D)

In Phase 1 and 2 studies already conducted, Metformin DR, with its targeted delivery to the distal small intestine, has shown the potential to be a safe and effective way to improve glycemic control in patients with T2DM and CKD with less systemic metformin exposure. The primary purpose of this …

  • 5 views
  • 14 Jun, 2022
  • 81 locations